TERMIS-AM 2026: What to Know About the Americas' Leading Regenerative Medicine Conference

WHAT THIS ARTICLE COVERS

This piece previews TERMIS-AM 2026, the Americas Chapter annual meeting of the Tissue Engineering and Regenerative Medicine International Society (TERMIS), set for November 15-18, 2026, at the Hilton New Orleans Riverside in New Orleans, Louisiana. We cover what the conference is, why it matters for the regenerative medicine field broadly, what's on the agenda, and who tends to get the most out of attending — useful context for anyone tracking where stem cell and tissue-engineering science is actually headed, as distinct from marketing claims made by individual clinics.

WHAT IS TERMIS-AM?

TERMIS is a global scientific society organized into regional chapters — Americas (AM), Europe (EU), and Asia-Pacific (AP) — that each hold their own annual or biennial meetings alongside a World Congress. The Americas Chapter supports TERMIS's broader mission across North, Central, and South America, convening academic researchers, clinicians, biomaterials scientists, and industry teams working in tissue engineering and regenerative medicine. It is not a commercial clinic conference or a patient-recruitment event; it's a peer scientific meeting where new, often early-stage, laboratory and translational findings are presented and debated among specialists. That distinction matters for readers evaluating regenerative medicine claims: conferences like this are where the underlying science is actually tested and critiqued, long before — if ever — it reaches real-world clinical products.

DATES AND LOCATION

TERMIS-AM 2026 runs November 15-18, 2026, at the Hilton New Orleans Riverside. These dates and the venue are confirmed consistently across TERMIS's own Americas Chapter page, the Manufacturing USA events listing (which co-hosts the event page), and the Advanced Regenerative Manufacturing Institute's (ARMI) event calendar — independent sources that align on the same window and location. The meeting is co-chaired by three professors, according to the chapter's official listing.

WHY THIS YEAR'S MEETING STANDS OUT

TERMIS-AM 2026 marks the organization's 20th anniversary, and organizers have built the program around the theme "Bench. Chip. Clinic. Where Y'at in Regeneration?" — a nod to both the New Orleans setting and the meeting's throughline of tracking research from basic laboratory work ("bench") through organ-on-chip and microphysiological modeling ("chip") toward genuine clinical translation ("clinic"). Listed conference topics include tissue engineering, biomaterials, organ-on-chip and microphysiological systems, regenerative medicine, cell therapy, 3D bioprinting, and biofabrication, alongside dedicated Topical Working Interest Group (TWIG) sessions on stem cells and cell therapies. That breadth is a genuinely encouraging sign for the field: it suggests regenerative medicine research is maturing past isolated lab curiosities into a more integrated pipeline connecting molecular tools, predictive models, and eventual patient application — though, as ever at this stage, most of what gets presented at a meeting like this remains preclinical or early translational work, not an approved therapy.

WHO SHOULD PAY ATTENTION

• Academic and industry researchers in tissue engineering, biomaterials, and cell/gene therapy looking to track emerging methods and potential collaborators.
• Regenerative manufacturing professionals, given the event's ties to ARMI and the BioFabUSA initiative, which focus on scaling biofabrication processes.
• Journalists, policy watchers, and informed patients who want to understand the distance between what's scientifically promising and what's clinically available — attending (or following coverage of) a meeting like this is one of the more reliable ways to gauge that gap directly from the researchers doing the work.
• Students and early-career scientists, since TERMIS chapters typically run dedicated trainee programming alongside the main scientific sessions.

As of this writing, detailed registration pricing and a finalized session-by-session agenda were still being published; readers planning to attend should check the official TERMIS-AM 2026 conference site directly for registration deadlines, abstract submission windows, and the full schedule as those details are finalized closer to the meeting.

Bottom Line

TERMIS-AM 2026 is a legitimate, verifiable scientific meeting — not a promotional event for any clinic or product — and its 20th-anniversary program looks like a genuinely useful barometer for where tissue engineering and regenerative medicine research stands heading into 2027. The "bench to chip to clinic" framing captures something real and encouraging about the field's trajectory, but readers should keep in mind that most content at academic conferences like this represents research in progress, not treatments ready for patients. For anyone trying to separate credible regenerative medicine science from overstated marketing, tracking what gets presented at venues like TERMIS-AM is one of the better ways to do it.